Results 141 to 150 of about 957 (170)

Population pharmacokinetic analyses for sulbactam–durlobactam using Phase 1, 2, and 3 data

open access: yesAntimicrobial Agents and Chemotherapy
ABSTRACT Sulbactam–durlobactam is a β-lactam/β-lactamase inhibitor combination approved in the United States for the treatment of hospital-acquired and ventilator-associated bacterial pneumonia caused by susceptible isolates of Acinetobacter baumannii–calcoaceticus in adults.
John O'Donnell   +2 more
exaly   +3 more sources

Physical compatibility of sulbactam/durlobactam with select intravenous drugs during simulated Y-site administration

American Journal of Health-System Pharmacy, 2023
Abstract Purpose Sulbactam/durlobactam is a combination antibiotic designed to target Acinetobacter baumannii, including carbapenem-resistant and multidrug-resistant strains. The objective of this study was to determine the physical compatibility of sulbactam/durlobactam solution during simulated Y ...
Victor H, Ruiz   +5 more
openaire   +2 more sources

Successful Treatment of Carbapenem-Resistant Acinetobacter baumannii Meningitis With Sulbactam-Durlobactam

Clinical Infectious Diseases
Abstract Background The treatment of carbapenem-resistant Acinetobacter baumannii/calcoaceticus complex (CRAB) presents significant treatment challenges. Methods We report the case of a 42-year-old woman with CRAB meningitis who ...
Pranita D Tamma   +10 more
openaire   +2 more sources

Evaluation of sulbactam-durlobactam disk diffusion and broth microdilution methods for Acinetobacter baumannii

International Journal of Antimicrobial Agents
The broth microdilution method was used as a reference method to evaluate the accuracy of sulbactam-durlobactam disk diffusion method for A. baumannii.In 2023, 504 nonduplicated A. baumannii isolated from 59 hospitals in China were tested by broth microdilution (M07) and disk diffusion method (M02) (10/10 µg) according to the CLSI M100 Ed34 standard ...
Xiaolan Hong   +7 more
openaire   +2 more sources

Sulbactam–durlobactam for Acinetobacter pneumonia

The Lancet Infectious Diseases, 2023
Ammara Mushtaq, Abhinandan Anand Raman
openaire   +1 more source

Sulbactam–Durlobactam for Carbapenem-Resistant Acinetobacter baumannii–calcoaceticus Complex Infections

American Journal of Therapeutics
Background: Antimicrobial resistance (AMR) is a major health crisis specifically associated with Acinetobacter. Among different Acinetobacter species, Acinetobacter baumannii is known as the greatest culprit concerning clinical significance. Of most importance, carbapenem-resistant A.
Nino Marzella   +4 more
openaire   +1 more source

Unraveling sulbactam-durlobactam: insights into its role in combating infections caused by Acinetobacter baumannii

Expert Review of Anti-infective Therapy
Carbapenem-resistant Acinetobacter baumannii (CRAB) is a critical priority pathogen posing a substantial threat to our public health due to its virulence and resistance to broad-spectrum antimicrobials. Sulbactam-durlobactam (Xacduro) is a newly approved β-lactam-β-lactamase inhibitor combination agent with potent in vitro and in vivo activity against ...
Yakun, Fu   +2 more
openaire   +2 more sources

Durlobactam, a Diazabicyclooctane β-Lactamase Inhibitor, Inhibits BlaC and Peptidoglycan Transpeptidases of Mycobacterium tuberculosis

ACS Infectious Diseases
Peptidoglycan synthesis is an underutilized drug target in Mycobacterium tuberculosis (Mtb). Diazabicyclooctanes (DBOs) are a class of broad-spectrum β-lactamase inhibitors that also inhibit certain peptidoglycan transpeptidases that are important in mycobacterial cell wall synthesis.
Mary Nantongo   +12 more
openaire   +2 more sources

Home - About - Disclaimer - Privacy